BARDA Extends Chimerix Smallpox Contract; Adds $13m
This article was originally published in Scrip
Executive Summary
The Biomedical Advanced Research and Development Authority (BARDA) has extended Chimerix contract to develop its oral antiviral brincidofovir as a medical countermeasure to treat smallpox for an additional 15 months, adding $13m more in funding.